The need for new antibiotics

Clinical Microbiology and Infection, Supplement

Volumn 10, Issue 4, 2004, Pages 1-9

  Livermore, David M ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Antibiotics; Multiresistance; Pharmaceutical development

Indexed keywords

7 [[(2 AMINO 5 CHLORO 4 THIAZOLYL)(HYDROXYIMINO)ACETYL]AMINO] 3 [[3 [[(2 AMINOETHYL)THIO]METHYL] 4 PYRIDINYL]THIO] 8 OXO 5 THIA 1 AZABICYCLO[4.2.0]OCT 2 ENE 2 CARBOXYLIC ACID; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; COLISTIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DORIPENEM; ERTAPENEM; FOSFOMYCIN; FUSIDIC ACID; GARENOXACIN; GEMIFLOXACIN; GENTAMICIN; ISEPAMICIN; LINEZOLID; METICILLIN; MINOCYCLINE; MOXIFLOXACIN; NEW DRUG; NITROFURANTOIN; ORITAVANCIN; PENICILLIN DERIVATIVE; PENICILLIN G; PEPTIDE DEFORMYLASE INHIBITOR; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SITAFLOXACIN; SPECTINOMYCIN; SULBACTAM; TEICOPLANIN; TELITHROMYCIN; TETRACYCLINE; TIGECYCLINE; TRIMETHOPRIM; UNCLASSIFIED DRUG; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; DRUG DESIGN; DRUG HYPERSENSITIVITY; ENTEROBACTERIACEAE; GONORRHEA; GRAM NEGATIVE BACTERIUM; HEALTH CARE PERSONNEL; HOSPITAL INFECTION; HUMAN; MEDICAL SPECIALIST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PATHOGENESIS; PENICILLIN RESISTANCE; PNEUMONIA; POLITICS; PRESCRIPTION; PRIORITY JOURNAL; PSEUDOMONAS; RISK ASSESSMENT; SPECIES DIFFERENCE; STREPTOCOCCUS PNEUMONIAE; TUBERCULOSIS; UNITED KINGDOM; URINARY TRACT INFECTION; ANIMAL; BACTERIAL INFECTION; INFECTION CONTROL; METABOLISM; MICROBIOLOGY; MULTIDRUG RESISTANCE; PHARMACEUTICS; PUBLIC HEALTH; REVIEW; SYNTHESIS; COMMUNICABLE DISEASE; HOSPITAL;

ACINETOBACTER; ENTEROBACTERIACEAE; NEGIBACTERIA; PSEUDOMONAS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; HUMANS; INFECTION CONTROL; PUBLIC HEALTH; TECHNOLOGY, PHARMACEUTICAL;

EID: 16644364407     PISSN: 14709465     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1465-0691.2004.1004.x     Document Type: Article

References (45)

1. House of Lords Select Committee on Science and Technology. Resistance to Antibiotics and Other Antimicrobial Agents, Session 1997-8. TSO 1998.
2. UK Standing Medical Advisory Committee (SMAC). The Path of Least Resistance. Department of Health, London 1998.
3. European Commission BD. Opinion of the Scientific Steering Committee on Antimicrobial Resistance, Brussels 2003.
4. Anonymous. WHO global strategy for containment of antimicrobial resistance. Geneva: World Health Organization 2001.
5. Interagency Task Force on Antibiotic Resistance. A public health plan to combat antimicrobial resistance. http://www.cdc.gov/drugresistance/actionplan/actionplan.pdf. 2003.
6. Livermore DM. Bacterial resistance origins, epidemiology, and impact. Clin Infect Dis 2003; 36 (Suppl. 1): S11-S23.
7. Gruneberg RN. Global surveillance through PROTEKT the first year. J Chemother 2002; 14 (Suppl. 3): 9-16.
8. Aarestrup FM, Seyfarth AM, Emborg HD, Pedersen K, Hendriksen RS, Bager F. Effect of abolishment of the use of antimicrobial agents for growth promotion on occurrence of antimicrobial resistance in fecal enterococci from food animals in Denmark. Antimicrob Agents Chemother 2001; 45: 2054-9.
9. Mendelson G, Yearmack Y, Granot E, Ben Israel J, Colodner R, Raz R. Staphylococcus aureus carrier state among elderly residents of a long-term care facility. J Am Med Dir Assoc 2003; 4: 125-7.
10. Wiener J, Quinn JP, Bradford PA et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999; 281: 517-23.
11. Soares S, Kristinsson KG, Musser JM, Tomasz A. Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s. J Infect Dis 1993; 168: 158-63.
12. Gillespie SH. Antibiotic resistance in the absence of selective pressure. Int J Antimicrob Agents 2001; 17: 171-6.
13. Lenski RE. The cost of antibiotic resistance - from the perspective of a bacterium. Ciba Found Symp 1997; 207: 131-40.
14. Livermore DM, Mushtaq S, James D et al. In-vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles. Int J Antimicrob Agents 2003; 22: 14-27.
15. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996; 9: 148-65.
16. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 2002; 8: 321-31.
17. Jones RN, Sader HS, Beach ML. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001). Int J Antimicrob Agents 2003; 22: 551-6.
18. Coelho JM, Woodford N, Turton J, Livermore DM. Multiresistant Acinetobacter in the UK. how big a threat? J Hosp Infect 2004; in press.
19. Lambert T, Gerbaud G, Courvalin P. Transferable arnikacin resistance in Acinetobacter spp. due to a new type of 3′-aminoglycoside phosphotransferase. Antimicrob Agents Chemother 1988; 32: 15-9.
20. Levin AS, Barone AA, Penco J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008-11.
21. Livermore DM. Threat from the pink corner. Ann Med 2003; 35: 226-34.
22. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998-2001. Antimicrob Agents Chemother 2003; 47: 1681-8.
23. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa, our worst nightmare? Clin Infect Dis 2002; 34: 634-40.
24. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288: 1251-4.
25. Lee K, Lim JB, Yum JH et al, bla(VIM-2) cassette-containing novel integrons in metallo-β-lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital. Antimicrob Agents Chemother 2002; 46: 1053-8.
26. Gales AC, Menezes LC, Silbert S, Sader HS. Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-β-lactamase. J Antimicrob Chemother 2003; 52: 699-702.
27. Livermore DM, James D, Reacher MH et al. Trends in fluoroquinolone (ciprofloxacin) resistance among Enterobacteriaceae from bactermias in England and Wales 1990-1999. Emerg Infect Dis 2002; 8: 473-8.
28. Karlowsky JA, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001 Antimicrob Agents Chemother 2003; 47: 1672-80.
29. Chow JW, Fine MJ, Shlaes DM et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115: 585-90.
30. Livermore DM, Brown DF, Quinn JP, Carmeli Y, Paterson DL, Yu VL. Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae? Clin Microbiol Infect 2004; 10: 84-5.
31. Yuan M, Aucken H, Hall LM, Pitt TL, Livermore DM. Epidemiological typing of klebsiellae with extended-spectrum β-lactamases from European intensive care units. J Antimicrob Chemother 1998, 41: 527-39.
32. Arlet G, Rouveau M, Casin I, Bouvet PJ, Lagrange PH, Philippon A. Molecular epidemiology of Klebsiella pneumoniae strains that produce SHV-4 β-lactamase and which were isolated in 14 French hospitals. J Clin Microbiol 1994; 32: 2553-8.
33. De Gheldre Y, Struelens MJ, Glupczynski Y et al. National epidemiologic surveys of Enterobacter aerogenes in Belgian Hospitals from 1996 to 1998. J Clin Microbiol 2001; 39: 889-96.
34. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001; 32 (Suppl. 2): S94-103.
35. Radice NE Power P, Di Conza J, Gutkind G. Early dissemination of CTX-M-derived enzymes in Scnith America. Antimicrob Agents Chemother 2002; 46: 602-4.
36. Bonnet R. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 2004; 48: 1-14.
37. Cooper BS, Stone SP, Kibbler CC et al. Systematic review of isolation policies in the hospital management of methicillin-resistant Staphylococcus aureus: a review of the literature with epidemiological and economic modelling. Health Technol Assess 2003, 7: 1-194.
38. Johnson AP, Aucken H, Cavendish S et al. Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK. Analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS). J Antimicrob Chemother 2001; 48: 144.
39. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124: 1789-97.
40. Johnson AP, Warner M, Carter M, Livermore DM. In vitro activity of cephalosporin RWJ-54428 (MC-02479) against multidrug-resistant gram-positive cocci. Antimicrob Agents Chemother 2002; 46: 321-6.
41. Entenza JM, Hohl P, Heirze-Krauss I, Glauser MP, Moreillon P. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob Agents Chcmother 2002; 46: 171-7.
42. Zumia A, Grange JM. Multidrug-resistant tuberculosis - can the tide be turned? Lancet Infect Dis 2001; 1: 199-202.
43. Woodford N, Ward E, Kaufmann CE. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases (ESBLs) in the UK. J Antimicrob Chemother; in press.
44. Fenton KA, Ison C, Johnson AP et al. Ciprofloxacin resistance in Neisseria gonorrhoeae in England and Wales in 2002. Lancet 2003; 361: 1867-9.
45. Corkill JE, Komolafe AJ, Neal TJ, Mortimore A, Alawattegama AB, Hart CA. Molecular epidemiology of endemic ciprofloxacin-resistant Neisseria gonorrhoeae in Liverpool. Int J STD AIDS 2003; 14: 379-85.